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Background: Cluster randomized trials (CRTs) present unique ethical challenges. In the absence of a uniform
standard for their ethical design and conduct, problems such as variability in procedures and requirements by
different research ethics committees will persist. We aimed to assess the need for ethics guidelines for CRTs among
research ethics chairs internationally, investigate variability in procedures for research ethics review of CRTs within
and among countries, and elicit research ethics chairs’ perspectives on specific ethical issues in CRTs, including the
identification of research subjects. The proper identification of research subjects is a necessary requirement in the
research ethics review process, to help ensure, on the one hand, that subjects are protected from harm and
exploitation, and on the other, that reviews of CRTs are completed efficiently.
Methods: A web-based survey with closed- and open-ended questions was administered to research ethics chairs
in Canada, the United States, and the United Kingdom. The survey presented three scenarios of CRTs involving
cluster-level, professional-level, and individual-level interventions. For each scenario, a series of questions was posed
with respect to the type of review required (full, expedited, or no review) and the identification of research subjects
at cluster and individual levels.
Results: A total of 189 (35%) of 542 chairs responded. Overall, 144 (84%, 95% CI 79 to 90%) agreed or strongly
agreed that there is a need for ethics guidelines for CRTs and 158 (92%, 95% CI 88 to 96%) agreed or strongly
agreed that research ethics committees could be better informed about distinct ethical issues surrounding CRTs.
There was considerable variability among research ethics chairs with respect to the type of review required, as
well as the identification of research subjects. The cluster-cluster and professional-cluster scenarios produced the
most disagreement.
Conclusions: Research ethics committees identified a clear need for ethics guidelines for CRTs and education
about distinct ethical issues in CRTs. There is disagreement among committees, even within the same countries,
with respect to key questions in the ethics review of CRTs. This disagreement reflects variability of opinion and
practices pointing toward possible gaps in knowledge, and supports the need for explicit guidelines for the
ethical conduct and review of CRTs.
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Cluster Randomized Trials (CRTs), that is, trials in which
the units of randomization are intact social units or
groups, rather than independent individuals, are an in-
creasingly common design in health research [1,2]. It is
convenient to distinguish between three kinds of CRTs de-
pending on the level of intervention: cluster-cluster trials
(experimental interventions administered to the entire
cluster as a unit), professional-cluster trials (experimental
interventions administered to health or other profes-
sionals), and individual-cluster trials (experimental inter-
ventions administered to patients or individuals) [3,4]. An
example of a cluster-cluster trial is the COMMIT study, in
which 22 communities in the United States and Canada
were randomized to evaluate a community-wide advertis-
ing campaign to reduce smoking [5]. In the Nexus trial, an
example of a professional-cluster trial, 247 primary care
practices were randomized to evaluate the effect of audit
and feedback and reminder messages on radiology refer-
rals [6], while in the bed net trial, an example of an
individual-cluster trial, 36 villages were randomized to
evaluate the impact of distribution of insecticide-treated
bed nets to individual citizens on malaria morbidity and
mortality in remote areas of Cambodia [7].
There are many aspects of CRTs that complicate their
ethical design, conduct and review (beyond the statistical
complications) [3,8-10]. In the absence of guidance tai-
lored to CRTs, researchers and research ethics committees
have had to rely on variable interpretation of existing re-
search ethics guidelines, which were developed primarily
with individually randomized trials in mind. This has likely
contributed to variation in how CRTs have been con-
ducted in practice, as well as in the requirements and de-
cisions by different research ethics committees [11,12].
Between 2008 and 2012, we conducted a mixed-methods
research project to develop internationally accepted, prin-
cipled guidelines for the ethical design, conduct, and re-
view of CRTs [13]. As part of the effort to develop these
guidelines, we conducted a web-based survey of chairs of
research ethics committees (Research Ethics Boards
(REBs) in Canada, Research Ethics Committees (RECs) in
the United Kingdom, Institutional Review Boards (IRBs)
in the United States). The main objectives of this survey
were to a) evaluate the need among research ethics com-
mittees for guidelines specific to CRTs, b) gather informa-
tion about the research ethics review process for CRTs at
their institutions, and c) elicit their views on ethical issues
in CRTs using a scenario-based approach.
Methods
Target population
The target population was chairs of research ethics com-
mittees (one per institution) in Canada, the United
States, and the United Kingdom that a) are currentlyactive, b) review health-related human subjects (that is,
biomedical) research, and c) review randomized con-
trolled trials.
Sample size
The target sample size for the survey was 300, based on
estimating the proportion of chairs who agree or
strongly agree that there is a need to develop research
ethics guidelines for CRTs. A total of 300 respondents
would be sufficient to allow a 95% two-sided confidence
interval to extend ± 5.7% around an expected proportion
of 50%, which is the proportion that yields the max-
imum width. Assuming a response rate of 50%, we antic-
ipated that we would need to survey all REBs in Canada,
all RECs in the United Kingdom, and a random sample
of IRBs from the United States. Our expected sample
sizes were therefore 90 to 100 Canadian chairs, 50 to 60
United Kingdom chairs, and 150 to 160 United States
chairs, for an overall total of 300 respondents.
Sampling strategy
Obtaining an adequate sampling frame for research eth-
ics committees in the three countries was challenging.
Figures 1, 2 and 3 present flow diagrams summarizing
the identification, sampling, and participation of re-
search ethics chairs in the United States, Canada, and
the United Kingdom. In the United States, we used a list
of 3,903 so-called IORGs (‘Institutional Review Board
Organizations’) provided by the Office of Human Re-
search Protections (OHRP). This list did not differentiate
between biomedical or nonbiomedical IRBs. To increase
the efficiency of sampling, we separated the IORGs into
two strata: the first stratum consisted of 190 IORGs suc-
cessfully matched to the top 200 National Institutes of
Health funded institutions [14] (and thus more likely to
be biomedical); the second consisted of the remainder of
the IORGs, from which we randomly sampled 210.
Among these, we used online searches to exclude those
that were clearly nonbiomedical. The final sample size in
the United States was 300.
In Canada we used a list of 252 ‘biomedical’ REBs sup-
plied by the National Council on Ethics in Human Re-
search (NCEHR). As this list was approximately 10 years
out of date, it was cross-checked against the list of
Canadian-based IORGs provided by the OHRP to obtain
updated contact information and to identify any add-
itional REBs. For those REBs not on the OHRP list, we
attempted to obtain their updated contact information
by conducting online searches, sending an email to the
contact on file, and making telephone calls. The final
sample size in Canada was 195 REBs.
In the United Kingdom, we used a list obtained from
the National Research Ethics Service (NRES) to identify
119 active RECs. We cross-checked this list against the
All IORGs in the 
United States
N = 3903
Stratum 2:
Remainder of IORGs
N = 3713
Random sample 
n = 210
Surveyed
n = 112
Response rate: 24/95 = 25.5%
- Declined:  4
- No response: 66
- Respondents: 24
Excluded:
- Ineligible: 12
- Undeliverable: 6
Excluded:
- non-biomedical: 95
- no contact info: 3
Stratum 1: 
Top 200 NIH-funded 
institutions 
All IORGs included
N = 190 
Surveyed
n = 188
Response rate: 62/172 = 36.0%
- Declined: 6
- No response:  104
- Respondents:  62
Excluded: 
- Ineligible: 15
- Undeliverable: 1
Excluded: 
- no contact info: 2
Figure 1 Flow diagram summarizing the identification and inclusion of Institutional Review Boards (IRBs) in the United States. IORGs,
Institutional Review Board Organization; NIH, National Institutes of Health.
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the OHRP and identified an additional 36 (mostly
university-based) RECs. The final sample size in the
United Kingdom was 152 RECs.
Survey questionnaire
After pre-testing [15], the final questionnaire consisted of
37 items and required 30 to 45 minutes to complete. The
first section of the questionnaire presented three scenarios
of CRT protocols that (hypothetically) had been submitted
at the chair’s institution. The scenarios are presented in
Table 1. Briefly, the first scenario was a cluster-cluster trial
to evaluate a mass media advertising campaign to increase
colorectal cancer screening; the second was a professional-
cluster trial of an educational intervention targeted at gen-
eral practitioners (GPs) to reduce imaging for nontraumatic
back and knee pain; the third was an individual-cluster trial
randomizing villages in Cambodia to evaluate effectiveness
of insecticide-treated bed nets against malaria. The ques-
tions following each scenario addressed the type of review
the study would undergo at their institution (full review, ex-
pedited review, no review, or don’t know) and which cluster
members they would consider to be research subjects.Options for research subjects varied in each scenario from
more inclusive (for example, all cluster members), to less
inclusive (for example, only those who received an inter-
vention or who participated in data collection). Open text
boxes were provided to allow respondents to explain their
answers. Additional questions addressed informed consent
procedures, and benefits and harms, and will be reported
elsewhere. The second section of the questionnaire ad-
dressed the perceived need for ethics guidelines for CRTs
and included space to make any other comments about
ethical issues in CRTs. A final section requested demo-
graphic and descriptive information.
Survey implementation
The survey was conducted between April and July 2011.
A series of five contacts, based on Dillman’s recommen-
dations for the implementation of mail and internet sur-
veys, was used [16]. An invitation was sent to the chair
or committee contact on file including the survey URL,
a unique password, and details of confidentiality. A
thank you and reminder email was sent to all contacts
1.5 weeks after the invitation, with reminder emails sent
3 and 5 weeks after the invitation. As a ‘special’ contact
Canadian REBs
List from NCEHR: N = 252
Additional from OHRP: N = 4
Stratum 2
Updated contact info from 
OHRP: N = 104
Surveyed
n = 102
Response rate: 42/86 = 48.8%
- Declined: 8
- No response: 36
- Respondents: 42
Excluded:
- Ineligible: 15
- Undeliverable: 1
Excluded:
-Pilot site: 2 
Stratum 1
No updated contact info: 
N = 126
Surveyed
n = 93
Response rate: 18/67 = 26.9%
- Declined: 4
- No response: 45
- Respondents: 18 
Excluded:
- Ineligible: 24
- Undeliverable: 2
Established contact: 75
-Ineligible: 24
-Updated info: 42
-Excluded duplicate: 8
-Excluded pilot site: 1
No contact: 51
Exclude: 
-Multiple REBs from the
same institution: 26
Figure 2 Flow diagram summarizing the identification and inclusion of Research Ethics Boards (REBs) in Canada. NCEHR, National
Council on Ethics in Human Research; OHRP, Office of Human Research Protections.
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veys, a final reminder was sent by postal mail approximately
8 weeks after the initial invitation. A $30 Amazon gift cer-
tificate was offered to each respondent as an incentive.
Data analysis
Categorical variables were described using frequencies
and percentages. Exact or asymptotic methods were used
to calculate 95% confidence intervals (CIs) of percent-
ages for the main outcomes. We conducted tests of asso-
ciation using chi-squared or Fisher’s exact tests as
appropriate. Verbatim comments from open text boxes
were selected to illustrate the range of perspectives.
Ethics approval
Participants were informed that participation is voluntary
and assured of the confidentiality of their responses. Sub-
mission of the questionnaire was considered as consent.
The study procedures were approved by the Ottawa Hos-
pital Research Ethics Board.Results
Response rates
Of 647 contacts surveyed, 105 were discovered to be ineli-
gible; of the remaining 542 chairs, 189 responded, giving
an overall response rate of 35%. Response rates were
slightly higher in Canada (39%) than in the United
Kingdom (35%) and the United States (32%) (P = 0.36). To
help understand why response rates were lower than
anticipated, we compared response rates by various as-
pects of the sampling design. First, we explored whether
outdated contact information was a factor within Canada.
We found that response rates were significantly higher
among those with updated contact information from the
OHRP list (49% versus 27%, P = 0.006). Next, we explored
whether the inclusion of nonbiomedical committees was a
factor within the United States. We found that response
rates were higher among the top funded NIH institutions
(more likely to be biomedical) (36% versus 26%, P = 0.08).
In the United Kingdom, we compared response rates
among university (29%) and National Research Ethics
United Kingdom RECs
List from NRES: N = 119
Additional from OHRP: N = 36
Stratum 2: NRES list 
N = 118
Surveyed
n = 118
Response rate: 37/102 = 36.3%
- Declined: 5
- No response: 60
- Respondents: 37
Excluded: 
- Ineligible: 15
- Undeliverable: 1
Stratum 1: OHRP list 
N = 34
Surveyed
n = 34
Response rate: 6/21 = 28.6%
- Declined: 4
- No response: 11
- Respondents: 6 
Excluded:
- Ineligible: 13
- Undeliverable: 0
Excluded: 
- Multiple at one institution: 2
- Pilot site: 1
Figure 3 Flow diagram summarizing the identification and inclusion of Research Ethics Committees (RECs) in the United Kingdom.
NRES, National Research Ethics Service; OHRP, Office of Human Research Protections.
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ence (P = 0.50).
Characteristics of respondents
Table 2 presents characteristics of participating ethics
committees and chairs in the three countries. There
were some notable differences among countries: partici-
pating committees in the United States tended to be in
existence longer than those in the United Kingdom (85%
established before 1990 in the United States versus only
27% in the United Kingdom). Respondents in the United
States reviewed a median of 30 protocols per month,
compared to 5 and 8 in Canada and the United Kingdom
respectively. Approximately two-thirds of respondents in
Canada and the United Kingdom reported that they
reviewed at least one CRT per year, compared to 92% of
respondents in the United States. Only three committees
(all in the US) indicated that they had guidelines in place
for CRTs, and only eight in total indicated that they were
aware of any guidelines for CRTs.Perceived need for guidelines
Table 3 presents respondents’ perceived need for ethics
guidelines. Overall, 144 chairs (84%, 95% CI 79 to 90%)
agreed or strongly agreed that there is a need for ethics
guidelines for CRTs, 158 (92%, 95% CI 88 to 96%) that re-
search ethics committees could be better informed about
distinct ethical issues surrounding CRTs, and 52 (31%, 95%
CI 24 to 38%) that ethics application forms ought to be de-
signed separately for the CRT design. These responses were
not significantly different among the three countries (re-
sults not shown). They were also not significantly associ-
ated with experience reviewing CRTs: agreement with the
need for guidelines was 84% versus 85% (P = 0.82), and
agreement that committees could be better informed 98%
versus 91% (P = 0.10) among committees with and without
prior experience reviewing CRTs, respectively.
Types of review required for each scenario
Figure 4 presents the type of review that would be re-
quired for each scenario. There was large variability
Table 1 Description of three scenarios of cluster randomized trials presented in survey
Scenario Description
Cluster-cluster trial (mass media advertising for
colorectal cancer screening)
A researcher at your institution is proposing a cluster randomized trial to evaluate a radio,
television, and billboard advertising campaign aimed at increasing the proportion of
community residents who receive colorectal cancer screening according to well-accepted
national guidelines. Cluster randomization is used because the intervention (the advertising
campaign) is delivered to the community as a whole. Twenty cities will be randomly assigned
to either the intervention group or a control group receiving no intervention. A random
sample of 500 residents in each city will be surveyed before the intervention, and a separate
random sample of 500 residents in each city will be surveyed after the intervention, to
determine the proportions that have been screened. The surveys will be conducted by
telephone using random digit dialing. No personally identifying information will be collected
in the surveys.
Professional-cluster trial (professional education
to reduce imaging)
A researcher at your institution is proposing a cluster randomized trial to evaluate an
educational intervention designed to reduce unnecessary requests for X-rays in accordance
with well-accepted national guidelines (which have been widely available for two years) for
patients with nontraumatic back and knee pain. All 250 general practices in the study area will
be randomly assigned to either the educational intervention or a control group. The guidelines
will be mailed to all general practitioners (GPs) in intervention and control practices, but
intervention GPs will additionally receive regular reminder messages about the guidelines
by mail, as well as feedback about the number of X-rays ordered by their whole practice
compared with requests made by all GPs in the study. Study outcome 1 is the number of
X-rays ordered per thousand patients using data routinely collected by radiology departments.
These data will be sent to the researchers with GP identifiers included, to allow the researchers
to prepare feedback to the practices about their number of X-ray requests. Study outcome 2
is the percentage of X-ray requests that are concordant with the guidelines, determined by
researchers reviewing and collecting anonymized data from a randomly chosen subset of 100
patient records per practice.
Individual-cluster trial (distribution of bed nets
against malaria)
A researcher at your institution is proposing a cluster randomized trial to evaluate a malaria
prevention intervention. Thirty villages in Cambodia with a total population of 10,000 will be
randomly assigned to either an intervention group in which insecticide-treated bed nets will
be distributed to all residents (by delivering them to each household), or a control group in
which no bed nets will be distributed to any residents. Cluster randomization is used because
the bed nets can only be effective in preventing the spread of malaria if they are used by the
majority of residents in a village and because the investigators feel that it would not be
acceptable to distribute bed nets to only a random half of the residents in a village. Although
insecticide-treated bed nets have previously been shown to be effective against malaria in
most tropical and subtropical regions, there are differences in vector biting cycles and malaria
epidemiology in South East Asia that raise questions about the effectiveness of the insecticide-
treated bed nets in Cambodia. Village volunteers in both intervention and control villages will
be trained to recognize malaria symptoms and administer standard anti-malarial treatment.
Villagers will be told that they can consult the village malaria worker when unwell. Malaria
prevalence will be determined before and after the intervention using blood tests from
cross-sectional random samples of 250 people per village.
Taljaard et al. Trials 2014, 15:48 Page 6 of 14
http://www.trialsjournal.com/content/15/1/48among respondents in two of the three scenarios. In par-
ticular, for the cluster-cluster (mass media campaign to
increase colorectal cancer screening) and professional-
cluster (education of GPs to reduce imaging) scenarios,
approximately half of respondents indicated that these
studies would need to undergo full review. This variability
persisted even within countries: for the cluster-cluster sce-
nario, the percentages indicating full review in Canada,
the United Kingdom and the United States were 55%,
57%, and 42%, respectively, and for the professional-
cluster scenario, 65%, 51%, and 48%. On the other hand,
respondents were largely in agreement in the individual-
cluster scenario (bed nets to prevent malaria), with 86% of
respondents indicating that a full review would be re-
quired (88%, 87% and 85% in Canada, the United Kingdom,
and the United States, respectively). Respondents were
asked to explain their answers and selected explanations in
support of each type of review are presented in Tables 4and 5, by country, for the cluster-cluster and professional-
cluster scenarios. These responses illustrate the diversity of
views even within the same countries.
Identification of research subjects
The identification of research subjects is presented in
Table 6, sorted from most to least inclusive. In the cluster-
cluster scenario (mass media campaign to increase colorec-
tal cancer screening), there was considerable uncertainty as
to who would be considered research subjects. Although
the vast majority classified participants in the telephone
surveys as research subjects, there was uncertainty whether
all residents, only those exposed to the advertisements, or
only those screened were research subjects. Fewer than
one-third of respondents said that they would consider
all city residents (intervention and control arms) to be
research subjects. A selection of verbatim quotes sup-
porting more inclusive views is:
Table 2 Characteristics of participating ethics committees and chairs
Canada United States United Kingdom Total
(N = 60) (N = 86) (N = 43) (N = 189)
Response rate 39.2% (60/153) 32.3% (86/266) 35.0% (43/123) 34.9% (189/542)
Ethics committee characteristics
Year established
<1990 23 (42.6)a 66 (84.6) 10 (27.0) 99 (58.6)
1990 to 1999 14 (25.9) 9 (11.5) 13 (35.1) 36 (21.3)
> = 2000 17 (31.5) 3 (3.9) 14 (37.8) 34 (20.1)
# Protocols/month (Median, Q1-Q3) 5 (3 to 20) 30 (10 to 60) 8 (7 to 8) 10 (5 to 37.5)
Type of committeeb
University 18 (30.0) 49 (57.0) 8 (18.6) 75 (39.7)
Hospital/healthcare 41 (68.3) 41 (47.7) - 82 (56.2)
National Research Ethics Service - - 31 (72.1) 31 (16.0)
Other nonprofit 2 (3.33) 9 (10.5) 0 11 (5.8)
Other for-profit 5 (8.3) 2 (2.3) 0 7 (3.7)
Number of CRTs /year
None 18 (32.7) 3 (8.1) 27 (34.6) 48 (28.2)
1 to 5 35 (63.6) 28 (75.7) 38 (48.7) 101 (59.4)
>5 2 (3.6) 6 (16.2) 13 (16.7) 21 (12.3)
Have guidelines in place for CRTs 0 3 (3.8) 0 3 (1.7)
Aware of guidelines for CRTs 1 (1.8) 3 (3.8) 4 (10.8) 8 (4.7)
Ethics Chair characteristics
Years experience as chair
<2 9 (16.4) 12 (15.2) 9 (24.3) 30 (17.5)
2 to 5 27 (49.1) 28 (35.4) 12 (32.4) 67 (39.2)
>5 19 (34.5) 39 (49.3) 16 (43.2) 74 (43.3)
Years experience as member
<6 26 (47.3) 24 (30.4) 13 (35.1) 63 (36.8)
6 to 10 18 (32.7) 21 (26.6) 16 (43.2) 55 (32.2)
>10 11 (20.0) 34 (43.0) 8 (21.6) 53 (31.0)
Highest degreesc
Doctorate 24 (43.6) 36 (45.0) 17 (46.0) 77 (44.8)
Medical 23 (41.8) 43 (53.8) 13 (35.1) 79 (45.9)
Masters 16 (29.1) 10 (12.5) 11 (29.7) 37 (21.5)
Undergraduate 4 (7.3) 4 (10.8) 2 (2.5) 10 (5.8)
a Table entries represent number (%) unless otherwise indicated.
bA committee can be classified as more than one type.
cA chair can indicate more than one degree.
CRT, cluster randomized trial.
Table 3 Need for ethics guidelines for cluster randomized trials (CRTs): number (%) agreeing or strongly agreeing
with each statement
Canada United States United Kingdom Total
(N = 55) (N = 79) (N = 37) (N = 175)
There is a need to develop ethics guidelines for CRTs 45 (81.8) 67 (84.8) 32 (86.5) 144 (84.2)
Ethics committees need more information about ethical issues in CRTs 52 (94.6) 73 (92.4) 33 (89.2) 158 (92.4)
Application forms ought to be designed separately for CRTs 19 (35.2) 24 (30.8) 9 (24.3) 52 (30.8)
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Figure 4 Type of review indicated by respondents for the cluster-cluster, professional-cluster, and individual-cluster scenarios.
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protections required depends on the protocol itself,
potential harms or burdens, potential benefits, what
would happen anyway and what happens specifically
because of the research. All this will vary.
2. United Kingdom: The intervention is targeted at the
entire community, not only those who undergo
screening.
3. United States: All residents in the intervention cities
are potentially exposed to effects in the information
campaign, and thus should be protected from effects
of inappropriate content, no matter whether they
actually were exposed to the advertisements. (For
example, a spouse might hear the advertisement and
prompt the other spouse to schedule screening.)
Examples of less inclusive views are:
1. Canada: No data is collected from all residents, only
those sampled. Advertising for clinical procedures
with or without generic advice is a normal
experience of everyday life.
2. United Kingdom: The intervention is the advertising
so those not exposed and not questioned are no
different to those citizens in any uninvolved city.
The screening itself is not research;- it is a standard
health process which a proportion of citizens would
choose to undergo regardless.
3. United States: The entire population cannot be
considered as research subjects, both from a
practical and study design perspective. Some may be
affected by the advertising, but there are myriad
ways for individuals to encounter similar messagesand it would be virtually impossible to know what
influenced their ultimate behavior. The residents
who are directly contacted can more legitimately be
considered as ‘research’ subjects, given their direct
participation in the survey instruments.
In the professional-cluster scenario (GP education to
reduce imaging), there was a similar degree of uncer-
tainty. Approximately two-thirds of respondents indi-
cated that they would consider GPs to be research
subjects (intervention and control arms). Nearly two-
thirds indicated that patients whose medical records are
reviewed and nearly 40% that patients whose aggregated
data are used to calculate imaging rates are research
subjects; fewer than one-quarter indicated that they
would consider all patients as research subjects. A selec-
tion of illustrative quotes that support more inclusive
views are:
1. Canada: All GPs in the intervention and control
practices even if their own habits aren’t being
collected, because results will reflect on the quality
of the practice in general and thus may impact on
all of the GPs practicing in that practice.
2. United States: Would be concerned about whether
study would have an impact on ordering of x-rays
overall, so even patients who present with other
than back or knee pain could be affected.
3. United Kingdom: Even if anonymised aggregated
data is collected technically the patients are
research subjects and the ethics committees are
acting on their behalf to protect the appropriate
use of their data.
Table 4 Illustrative verbatim explanations for the type of review required, by country: cluster-cluster scenario
Country Type of review Explanation
Canada Full review Full Board review would be recommended for the following reasons: a) community
consent versus individual consent, b) there is an element of deception, c) the
treatment/intervention received is determined by randomization, d) the telephone
surveys deal with potentially sensitive topic (colorectal screening) and could result in
situations where there is a need for follow-up medical and/or psychological care.
Expedited Review is necessary due to ‘research’ component and to ensure privacy and patient
rights are protected. Expedited as there is no experimental manoeuvre, screening
is according to national guidelines.
No review The researcher is outside our jurisdiction - They are using subjects who are unlikely
to be our patients. At the beginning, consent is not required except at the municipal
level. There is no financial liability to the hospital. There is no treatment intervention.
I see this as no different from the telephone surveys I receive now at home. It would
be polite and professionally correct to bring this to the ethics committee as an FYI.
If the researcher wanted to add gravitas to his/her survey they might ask for the
‘blessing’ of the ethics committee. However , as before, it not being done on hospital
property, involves no patients and no therapeutic intervention.
United Kingdom Full review The exceptions are minimal risk studies with small numbers of participants, which
have no contentious issues. In this case, 1,000 participants, approached by random
‘cold-call’ telephone with verbal consent required and no prior information, would
be rated by us as large and potentially contentious.
Expedited review The proposed trial deals with a situation where the normal practice is ‘no intervention’;
there’s no specific bowel screening promotion as described in the UK. Expedited review
would be to address whether the materials provided to the Mayors/Officials of the cities
involved enough information to understand the proposed research. There is low/no risk
to participating citizens and the interventions would be considered ‘light touch’ and of
low risk; unless of course review of the proposed telephone interview guidelines revealed
significant intrusive or alarming questions.
No review Because it is the effectiveness of the advertising campaign that is to be evaluated and
this in itself is not a medical intervention and I would regard the study as in support of
delivering an established standard of normal care.
United States Full review I think the questions raised by the methodology, in particular the randomization to a community
intervention without individual consent, would merit consideration by the full board.
Expedited review The study as described presents no more than minimal risk to the sample involved.
The dependent measure is related to behavior. The study is not inviting participants to get
a colorectal exam offered by the investigators. The study measures are related to the
effectiveness of an information campaign.
No review This is a survey, should be exempt 45 CFR 46.101 #2.
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1. United Kingdom: This trial is concerned with GPs -
the aim is simple - if given feedback will GPs reduce
the number of X ray requests - patients are not sub-
jects - they are just a source of data.
2. United States: The patients are not having an
intervention performed on them directly and are
therefore not research subjects. The physicians are
being active participants and are therefore research
subjects.
In the individual-cluster scenario (bed nets to prevent
malaria) there was much less variability. Almost all
chairs indicated that residents who provided blood sam-
ples (98%), and the majority of those who received bed
nets (88%), would be considered research subjects. A
slightly lower percentage (80%) would also consider resi-
dents in control communities (not receiving bed nets) tobe research subjects. Approximately 40% included village
malaria workers as research subjects.
Any other comments
Several respondents identified a concern with respect to
cluster-level interventions that may be considered as ex-
perimental interventions at the individual level; they
were concerned that such studies may lack an appropri-
ate rationale for the adoption of the CRT design, and
that it may be an attempt by researchers to sidestep con-
ventional informed consent requirements. These con-
cerns are included below as verbatim quotes:
1. Canada: Occasionally I have been aware of cluster
trials that deal with the evaluation of different forms
of practice that are currently being done and for
which there are no current standards of care
proscribed. For example, use of different sets of
antibiotics after cardiac interventions or changes in
Table 5 Illustrative verbatim explanations for the type of review required, by country: professional-cluster scenario
Country Type of review Explanation
Canada Full review This study would require REB approval because there is an intervention, patient data is collected
and consent is not planned. There is the onus to review fully given the lack of a consent process,
regardless of the reason.
Expedited Meets all Tri-Council Policy Statement (TCPS) criteria for minimal risk.
No review This seems to be more akin to a Quality Improvement study of whether an educational intervention
and reminders about an accepted Clinical Guideline leads to greater acceptance and adoption of
these practices. Our REB does not review these, but there is a process of review and support for these
studies through our Quality and Risk Management Dept. All interventions and practices are clinically
indicated and data is only aggregate.
United Kingdom Full review Because of the randomisation of practices. Otherwise could have been considered as a service evaluation
and therefore not require review (potentially!)
Expedited review Minimal risk, using routinely collected data, assuming that patient data for outcome 2 are properly
anonymised and secure, and do not require information that is outside normal clinical care.
No review This is classic improvement methodology and would not need review.
United States Full review There is an issue of physicians being known to the researchers and the potential for data about their
behavior that could be used to potentially harm the physician’s reputation due to information about
his/her medical practices (x-rays).
Expedited review We would not consider an educational intervention as treatment. The educational intervention mailing
established imaging guidelines is clearly minimal risk. Measuring radiology imaging by GP is not private
information and routinely measured by many external entities. The outcome measures of number
X-rays/thousand and anonymized medical records review would meet Expedited review categories.
No review This seem to be primarily a trial to determine quality of care and use or misuse of diagnostic studies.
No patient is harmed or helped by the study. It may help cost containment. It doesn’t need to come
to the IRB.
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following: What really constitutes an intervention
(using (Tri-Council Policy Statement) as a guide)
and therefore when should consent be obtained;
where would one draw the line between quality
assurance and research? Concern has also been
raised about whether the trend for cluster trials is a
mechanism to avoid the rigors of the consent
process. Are letters of information sufficient to
address this concern. These issues relate not so
much to the large population studies, but rather to
cluster trials being conducted in the current health
care settings.
2. Canada: Most of the discussions we have had when
discussing cluster RCT centered around the
informed consent issues, when to waive consent,
how much information to reveal, how much choice
is there when the whole institute is already
randomized to a certain intervention or not, and
how to address situations where it is not beneficial
for certain patients to be enrolled in the wrong
intervention for their situation. For example, in a
hospital cluster RCT where one hospital is
randomized to a certain surgical process while the
other is not, patients who are contraindicated to
that surgery who end up in the intervention arm
should be given the opportunity to refuse
participation. In which case, they may have to be
referred to another hospital not in the study.Another identified concern was determining whether a
study constitutes research as opposed to program evalu-
ation or quality improvement:
1. United States: We have struggled with many issues
related to this- when the Ministry of a country plans
a roll out of a public health intervention and the re-
search is to perform a cluster analysis of the inter-
vention, what is research, what is a public health
program evaluation and similar issues. This is still a
topic of discussion and debate, especially between
the IRB and international researchers.
Discussion
This survey was conducted as part of a five-year project
studying ethical issues in CRTs [13]. Following a series of
empirical studies (including this survey), an in-depth eth-
ical analysis, and an extensive consensus process, the
Ottawa Statement ─ the first comprehensive ethics guide-
lines specific to CRTs ─ was published in November 2012
[17]. Although the survey was fielded before development
of the Ottawa Statement, it is informative to interpret the
results of the survey in light of the recommendations in
the Ottawa Statement.
The first aim of the survey was to determine the need
for research ethics guidelines for CRTs among research
ethics chairs internationally. We found that 84% of re-
search ethics chairs overall recognized the need for eth-
ics guidelines for CRTs and 92% the need for education
Table 6 Identification of research subjects in the cluster-cluster, professional-cluster, and individual-cluster trial
scenarios
Frequency (%)
Cluster-cluster trial Yes No
All city residents in the intervention arm 50 (29.8)a 118 (70.2)
All city residents in the control arm 46 (27.9)a 119 (72.1)
Residents exposed to the advertisements 68 (39.5)a 104 (60.5)
Residents in intervention arm receiving screening 72 (42.1)a 99 (57.9)
Residents participating in the telephone survey 171 (90.0)a 19 (10.0)
Professional-cluster trial Yes No
Patient-level:
All patients in the practices 37 (22.6) 127 (77.4)a
Patients presenting with back or knee pain 63 (38.4) 101 (61.6)a
Patients providing data for study outcome 1 64 (38.6) 102 (61.5)a
Patients providing data for study outcome 2 104 (62.3)a 63 (37.7)
Professional-level:
All GPs in intervention practices 109 (66.9)a 54 (33.1)
All GPs in control practices 103 (63.6)a 59 (36.4)
GPs whose patients present with back or knee pain 127 (77.4)a 37 (22.6)
Individual-cluster trial Yes No
Residents receiving bed nets 158 (88.3)a 21 (11.7)
Residents in control arm receiving no bed nets 139 (79.9)a 35 (20.1)
Residents providing blood samples 177 (98.3)a 3 (1.7)
Village malaria workers 58 (36.7) 100 (63.3)a
aIndicates that an answer is in agreement with the Ottawa Statement. GPs, general practitioners.
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perceived need for guidelines was not significantly asso-
ciated with experience reviewing CRTs, which suggests
that the need remains widespread and is not declining
with experience. In our survey of 182 trialists (authors of
CRTs) conducted as part of the five-year project, 74%
(95% CI 67 to 80%) agreed or strongly agreed that there
is a need to develop ethics guidelines for CRTs and 70%
(95% CI 63 to 77%) that ethics committees could be bet-
ter informed about distinct ethical issues surrounding
CRTs [12]. Surprisingly, the proportions of research eth-
ics chairs indicating the need for ethics guidelines were
higher than the corresponding proportions of trialists.
Our second aim was to investigate research ethics re-
view procedures for three different kinds of CRTs. We
found that there was little agreement among committees
in the type of ethics reviews required in the cluster-
cluster and professional-cluster scenarios, both among
and within countries. Whereas regulatory differences
may explain differences among countries, it does not
explain within-country variability. Whereas there was
more agreement in the individual-cluster scenario, clus-
ter-cluster trials and professional-cluster trials often
evaluate public health programs or quality improvementinitiatives, and it is not always clear if such trials ought
to be considered research and undergo research ethics
review. According to Recommendation 1 in the Ottawa
Statement, all CRTs involving human research partici-
pants must be submitted to a research ethics committee.
This includes CRTs evaluating quality improvement and
knowledge translation interventions, and those in educa-
tion or public health research. The type of ethics review
is subject to the discretion of the committee; research
ethics committees ought to undertake a proportional ap-
proach to the review of study protocols such that CRTs that
pose substantial risk or involve vulnerable participants
ought to receive intensive scrutiny, whereas CRTs that pose
low risk and do not involve vulnerable participants may be
eligible for an expedited or delegated review. Although the
majority of respondents in all three scenarios agreed that
some type of review is required (as opposed to no review),
variability in the type of review required is an important
finding as it reflects fundamental differences among com-
mittees with respect to the perceived level of risk associated
with each scenario and the perceived vulnerability of those
who might be considered participants. The type of review
may have implications with respect to the level of scrutiny
a protocol will receive during the review process, the
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quired to complete the review process.
Our third aim was to characterize the views of re-
search ethics chairs on the identification of research sub-
jects. The proper identification of research subjects is of
considerable importance, as only those cluster members
who are research subjects properly fall under the protec-
tion of research ethics committees and the regulations
under which they operate. We observed substantial vari-
ability among chairs in all three countries with respect
to the identification of research subjects in the cluster-
cluster and professional-cluster scenarios. The individ-
ual-cluster scenario, which most resembles a standard
randomized controlled trial, presented less disagreement.
According to the Ottawa Statement [17,18] a research
participant is defined as any individual whose interests
may be affected as a result of study interventions or data
collection procedures; that is, any individual who is the
recipient or the direct target of a study intervention
(whether an individual level or cluster level interven-
tion), with whom researchers interact for study pur-
poses, or about whom identifiable private information is
collected. In the cluster-cluster scenario, fewer than one-
third of chairs would consider residents in intervention
and control communities to be research subjects, even
though study interventions are targeted at them. It is a
unique characteristic of CRTs that there can be partici-
pants at both individual and cluster levels. Surprisingly,
in agreement with the Ottawa Statement, two-thirds of
chairs indicated that they would consider health profes-
sionals to be research subjects. On the other hand,
nearly 40% would consider patients whose health profes-
sionals participate in a knowledge translation interven-
tion and who contribute only aggregate data (that is,
practice-level imaging rates) to be research subjects. It
is possible that those respondents who were broadly in-
clusive in identifying individuals who may be subjects
in a CRT were doing so because they believed that the
study required full ethics review and this would be one
way to that end. Furthermore, although the need to
seek informed consent is a separable issue [19], it is
possible that chairs conflated the identification of re-
search participants with the need to seek informed
consent. The Ottawa Statement may help to avoid
conceptual confusion by providing clarity on these im-
portant questions.
To the best of our knowledge, this is the first study to
compare deliberations and decisions among research
ethics committees in the review of CRTs. Although the
scenarios were hypothetical, they represent three com-
mon settings where CRTs are used and are based on
published CRTs. Participants in our survey provided per-
spectives from chairs in three countries: Canada, the
United States, and the United Kingdom, and representeda variety of institutions: universities, hospitals, non-
profit and for-profit, and varying degrees of experience.
Our study provides empirical data of variability among
committees both within and among countries in key de-
cisions about the ethics review and conduct of CRTs. Al-
though variability among ethics committees is not
necessary morally problematic [20], these decisions have
clear repercussions for the ability of research ethics
committees to fulfill their purpose which includes pro-
tecting the rights and wellbeing of all research partici-
pants and to provide independent, competent, and
timely review of the ethics of proposed studies [21].
Our study has two main limitations. First, our re-
sponse rate was low and results may therefore not be
representative. There can be many reasons for the low
response. One is that our sampling frame was imperfect.
Despite our best efforts at obtaining updated contact in-
formation and screening out ineligible committees prior
to sampling, 105 of the 647 sampled committees (16%)
either indicated that they were ineligible (that is, were
nonbiomedical or did not review randomized controlled
trials) or had invalid email addresses. Our stated re-
sponse rate is conservatively calculated, meaning that all
non-respondents are assumed to be eligible and included
in the denominator of the response rate. The type of
contact information varied: in some cases we had an
email address for a named chair, while for others, only a
central contact was available. Our analyses of response
rates showed that response rates were higher among com-
mittees with more recent contact information; it was also
higher among committees at NIH-funded institutions
(more likely to be biomedical). Finally, our survey was rela-
tively long and presented three complex scenarios; research
ethics chairs are busy professionals and may simply not
have had the time to complete the survey. Although
we do not have any information that would allow us to
investigate differences between respondents and non-
respondents, we have no reason to expect answers of
non-respondents to differ substantially from those
observed in this survey.
A second limitation is that the descriptions of the sce-
narios were necessarily brief. In practice, ethics commit-
tees would have access to the full study protocol. It is
possible that at least some of the variability observed is
due to the lack of clarity or incompleteness of the infor-
mation provided. However, we believe that the most
relevant information was presented in each scenario,
and the results are in line with findings from our survey
of CRT investigators, which suggested that there are
substantial challenges in practice. We were pleasantly
surprised by the level of detail and thoughtfulness put
into the open text responses. It was apparent that the
majority of respondents paid careful consideration to the
details provided in the scenarios and presented well-
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spondents understood that the scenarios were intended
to trigger reflection on a certain class of study, rather
than limit their consideration to those details provided
in the survey alone.
Conclusions
CRTs are an important research design, but research
ethics committees and investigators need guidance as to
ethically appropriate practices. Our scenario-based sur-
vey provides empirical evidence of the likely variability
of opinion and practices within and among countries,
pointing towards possible gaps in knowledge, and fur-
ther supporting the need for guidelines.
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